Board of directors
Dr. Pierre-Henri Benhamou
Dr. Pierre-Henri Benhamou co-founded DBV Technologies in 2002, and has served as Chief Executive Officer from 2002 to the present and Chairman of board of directors since initial public offering on NYSE Euronext Paris in March 2012. With Pr. Christophe Dupont, he described for the first time and patented the epicutaneous method of immunotherapy and explored with the scientific team the wide range of applications of the method. Dr. Benhamou is a physician, specializing in pediatric gastroenterology. He has held numerous clinical and academic positions. He received the Altran Foundation Prize for Innovation in 2003 for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers and originated key scientific collaborations for us and has been instrumental in forming the Scientific Advisory Board. Dr. Benhamou holds an MD. in Medicine from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987. The board of directors believes that Dr. Benhamou’s leadership, deep knowledge of the company and scientific experience will allow him to drive DBV to the success.
George Horner III
Currently, Mr. Horner is a biotech executive consultant for several private companies in the United States and Europe. Previous, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington’s Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb across 4 continents, worldwide. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg, Chairman of the Board of Omthera Pharmaceuticals of Bedminster, New Jersey, USA, and member of the Durata Therapeutics board of directors.
Dr. Torbjörn Bjerke
Torbjorn Bjerke MD, contributes valuable skills and great expertise in the treatment of allergies and drug development as a result of his vast experience as CEO for Biolipox, Orexo and Karolinska Development. Dr Bjerke has more than 25 years of experience from the pharmaceutical industry also including Executive Vice President of the Research and Development at ALK-Abelló and prior to that occupied positions as Director of Inflammation Pharmacology at AstraZeneca and visiting scientist at Genentech Inc. Torbjorn also co-founded Action Pharma (sold to Abbott) and most recently TXP Pharma.
Michael J. Goller
Michael Goller is a Partner at Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Prior to joining Baker Brothers in 2005, Mr. Goller was an Associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Mr. Goller holds a B.S. in Molecular and Cell Biology from The Pennsylvania State University, and a Master's in both Biotechnology (School of Engineered and Applied Sciences) and Business Administration (Wharton School) from the University of Pennsylvania.
Daniel Soland most recently served as Senior Vice President and Chief Operating Officer of Viropharma, and currently serves on the Board of Tarsa Therapeutics.
In addition to his role at Viropharma, where he helped build the organizational and commercial infrastructure that resulted in an 11-fold increase in Viropharma’s share price during his tenure, Mr. Soland previously served as President of Chiron Vaccines, and helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals. At GlaxoSmithKline Biologicals, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a BS in Pharmacy degree from the University of Iowa.
Ms. Giraut is currently the Chief Financial Officer of bioMérieux, a worldwide leader in in-vitro diagnostics. She previously served notably as the Chief Financial Officer of Ipsen after holding various finance leadership positions in other worldwide organizations. She also serves since 2010 as a Director of Julius Baer Group Ltd. and Bank Julius Baer & Co. Ltd., the leading Swiss private banking group. She holds a Masters from the Institut National Agronomique (AgroParisTech) in Paris.
Ms. Mailys Ferrere is a Director, Head of the Large Venture Investment Activity at Bpifrance, France’s public investment bank, and DBV’s second largest shareholder. She graduated from Institut d’Etudes Politiques Paris, and began her career in 1985 with the General Inspectorate of Société Générale before working for multiple French banks in the Equity Capital Markets Origination department. Mailys has been an observer in DBV’s Board of Directors since the Initial Public Offering of the Company in the Euronext in March 2012
Julie O'Neill is currently Executive Vice President, Global Operations of Alexion, responsible for global manufacturing operations, as well as Alexion’s complete supply chain and quality operations. Before joining Alexion, she was Vice President of Operations and General Manager for Ireland at Gilead. Earlier in her career, Ms. O’Neill held leadership positions in operations, manufacturing and quality functions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She also serves as Chairperson for the National Standards Authority of Ireland and is a member of the Governing Body of University College Cork.